These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 27906544)
1. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease. Pflugfelder SC; Stern M; Zhang S; Shojaei A J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544 [TBL] [Abstract][Full Text] [Related]
2. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease. Paton DM Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115 [TBL] [Abstract][Full Text] [Related]
3. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117 [TBL] [Abstract][Full Text] [Related]
4. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Semba CP; Gadek TR Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762 [TBL] [Abstract][Full Text] [Related]
5. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723 [TBL] [Abstract][Full Text] [Related]
6. A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye. Hsueh PY; Ju Y; Vega A; Edman MC; MacKay JA; Hamm-Alvarez SF Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326657 [TBL] [Abstract][Full Text] [Related]
7. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. Periman LM; Perez VL; Saban DR; Lin MC; Neri P J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues. Du G; Du W; An Y; Wang M; Hao F; Tong X; Gong Q; He X; Jiang H; He W; Zheng M; Zhang D Med Chem Res; 2022; 31(4):555-579. PubMed ID: 35194364 [TBL] [Abstract][Full Text] [Related]
9. Force spectroscopy of the leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. Zhang X; Wojcikiewicz E; Moy VT Biophys J; 2002 Oct; 83(4):2270-9. PubMed ID: 12324444 [TBL] [Abstract][Full Text] [Related]
14. Low affinity of cell surface lymphocyte function-associated antigen-1 (LFA-1) generates selectivity for cell-cell interactions. Ganpule G; Knorr R; Miller JM; Carron CP; Dustin ML J Immunol; 1997 Sep; 159(6):2685-92. PubMed ID: 9300688 [TBL] [Abstract][Full Text] [Related]
15. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Watanabe T; Fan J Int J Cardiol; 1998 Oct; 66 Suppl 1():S45-53; discussion S55. PubMed ID: 9951802 [TBL] [Abstract][Full Text] [Related]